skip to Main Content

2023 Programme Overview

Session Provisional Timings Name Title
Wednesday 1st February Myrddin Rees & Åsmund Fretland Welcome & Programme Introductions
Registration and arrival drink in hotel 19:30
Welcome dinner in hotel and programme introduction 20:00
Thursday 2nd February 0800 – 0830 Richard Schulick, Denver
Session 1: Advances in the surgical management of HPB disease Opening Lecture
Pancreatic neuroendocrine tumours – when to resect
0830 – 0850 Peter Kingham, New York Bariatric liver surgery: trimming the fat
0850 – 0910 Camille Stewart, Denver Malignant melanoma liver metastases
0910 Free papers FP01 and FP02
1615 Coffee and Posters
(Screen 1: AB01 – AB08  Screen 2: AB09 – AB015
Session 2: 1700 – 1730 Chris Wolfgang, New York The 10-blade – A double edged sword
1730 – 1750 Damian Mole, Edinburgh Next-gen discovery of hidden secrets of acute pancreatitis
Bench to bedside 1750 – 1810 Duncan Jodrell, Cambridge Can an old drug learn a new trick?  The ATRiUM clinical trial
1810 – 1820 Free papers FP03 and FP04
Dinner at the hotel 1930
Friday 3rd February 0800 – 0820 Bas Groot Koerkamp, Rotterdam Supra-ampullary stenting for cholangiocarcinoma
Session 3:Clinical trials 0820 – 0840 Fieke Frohling, Glasgow Personalising treatment for pancreatic cancer
0840 – 0900 Michael Lidsky, Durham, North Carolina Hepatic Arterial Infusion Pump Chemotherapy – is it time for widespread adoption?
0900 – 0915 Remon Korenblik, Maastricht Results of the prospective international multicentre DRAGON 1 trial
Free papers FP05 and FP06
Faculty Lunch (separate booking and payment required – spaces limited) at Chalet Spinale (previously Chalet Fiat) Restaurant ( 1300 For those confirmed to attend, please arrive promptly at 13.00.  Skiers should proceed to Monte Spinale. Non-skiers will need to proceed into town on the hotel bus and take the Spinale cable car.
1615 Coffee and Posters
(Screen 1: AB016 – AB023  Screen 2: AB024 – AB031
Session 4: 1700 – 1720 David Iannitti, Charlotte Efficacy of hepatic tumour MWA: Variables that impact local recurrence
1720 – 1740 Reto Bale, Innsbruck What does ablation need to become a full alternative to resection of liver tumours?
Technology Session 1740 – 1800 Sanjay Gupta, Southampton Chemosaturation treatment of melanoma liver metastases
1800 – 1830 Joris Erdmann, Amsterdam Quantitative scintigraphy versus MRI assessment of liver function
Myrddin Rees, Basingstoke
1830 Free papers FP07 and FP08
Dinner at the hotel 1930
Saturday 4th Feb 0800 – 0820 Arjun Takhar, Southampton Improving surgeon performance with non-technical skills
Session 5:“How we do it” session 0820 – 0840 Marc Besselink, Amsterdam How to run a clinical trial
0840 – 0900 Steve Wigmore, Edinburgh How to review a paper
0900 – 0920 Mo Abu Hilal, Brescia How we do a laparoscopic distal pancreatectomy
0920 – 0940 Giovanni Marchegiani, Verona How we train for the open Whipple procedure
Session 6: 1700 – 1730 Peter Allen, Durham, North Carolina Are randomised surgical trials worth it?
1730 – 1800 Vinod Balachandran, New York mRNA vaccines for pancreatic ductal adenocarcinoma
Closing session 1800 – 1830 Marco del Chiaro, Denver Two continents and three heathcare systems!
1830 – 1900 David Tuveson, New York Research Foundations working to defeat pancreatic cancer
1900 Marc Bemelmans & Åsmund Fretland Closing remarks
ALPS farewell dinner and ALPS Farewell Dinner and Prizegiving 2000

Free papers

FP01 Routine sampling of lymph node station 16b1, 9, and 8a during pancreatoduodenectomy for pancreatic and periampullary carcinoma (PANODE): a prospective multicenter study Annelie Suurmeijer
FP02 Ca19.9 as a marker of recurrence in resected biliary tract cancers.
Victoria Morrison-Jones
FP03 Expression of markers of hepatocyte apoptosis and proliferation during ex-vivo perfusion of isolated human liver segments  Trisha Kanani
FP04 Identifying genetic mutation status in patients with colorectal liver metastases using radiomics based machine learning models  Michiel Zeeuw
FP05 Patient reported outcomes after laparoscopic versus open hemihepatectomy within an enhanced recovery program, the ORANGE-II-PLUS Randomized Clinical trial: A Quality of Life and Body image analysis  Bram Olij
FP06 Simultaneous resection of colorectal cancer and synchronous liver metastases: what determines the risk of unfavorable outcomes? An international multicenter retrospective cohort study Jasper Sijberden
FP07 Nationwide implementation of best practices in pancreatic cancer care (PACAP-1): stepped-wedge cluster randomized trial Simone Augustinus
FP08 Women receive less surgical and systematic treatment for non-metastatic pancreatic cancer: a nationwide retrospective real-world cohort study  Anne Gehrels


AB01 Prevention of post hepatectomy liver failure in cirrhotic patients undergoing laparoscopic liver resection: Has the round ligament to be preserved?
Federico Gaudenzi
AB02 Long-term complications after distal pancreatectomy: a nationwide analysis
Nanske Biesma
AB03 Late cholangitis after pancreatoduodenectomy: a common complication with or without anatomical biliary obstruction  Anne Claire Henry
AB04 Functional assessment by hepatobiliary scintigraphy is superior to volumetry to predict post operative liver failure after major liver resection  Pieter Arntz
AB05 PVE/HVE improves survival compared to PVE alone – A survival analysis of the retrospective multicenter DRAGON 0 cohort  Jan Heil
AB06 Rescue ALPPS after hepatic vein embolization and vice versa – first cases by the DRAGON Collaborative  Sinead James
AB07 Supervised home-based exercise prehabilitation in unfit patients for pancreatic surgery: preliminary results of a multicenter feasibility study  Nicole Hildebrand
AB08 The BPRECISE Pilot Trials: Study protocol for the development of a microfluidics droplet-based drug screen (MFDS) in the personalised treatment of primary and secondary hepatic, pancreatic and biliary tumours  Francesca Pennetta
AB9 Radiation response assessment in organoids derived from patients with pancreatic cancer  Iris W.J.M. van Goor
AB10 Expression of non-specific cytotoxic cell receptor protein 1 homolog (NCCRP1) in anaplastic carcinoma of the pancreas  Mai Nakamura
AB11 Signal transduction pathway analysis in pancreatic cancer in search for new therapeutic targets Leon Raymakers
AB12 Healthcare inequalities and outcomes from acute pancreatitis  Trisha Kanani
AB13 Measurement of intra-abdominal pressure using transcutaneous sensors
Bostjan Plesnik
AB14 Open cholecystectomy training on a porcine hepatic ex-vivo perfusion model – A surgical trainee’s perspective  Wajith Hussain Zahir Hussain
AB15 Operative risk factors for technical failures following surgical microwave ablation  Ansley Ricker
AB16 Intraoperative electrochemotherapy for the treatment of hepatocellular carcinoma: long-term results Hana Zavrtanik
AB17 Robotic versus laparoscopic liver resection: propensity matched comparison of two-center experience  Lorenzo Bernardi
AB18 Nationwide implementation and outcomes of minimally invasive distal pancreatectomy  Maarten Korrel
AB19 The effect of microwave and radiofrequency ablation (MWA/RFA) on liver volume in patients with primary and secondary liver tumours – a retrospective analysis.
Robrecht Knapen
AB20 Artificial intelligence for identification of focal lesions in intraoperative liver ultrasonography Yiftach Barash
AB21 Diagnostic accuracy of cross-sectional and endoscopic imaging in malignant and benign ampullary tumours – a systematic review  Anouk de Wilde
AB22 Application of the SUPERA self expanding stent in biliary tree obstruction, our recent experience  Amit Talmon
AB23 Treatment of recurrence and post-recurrence survival after different primary treatment strategies for patients with pancreatic cancer  Paul Andel
AB24 Improved staging for localized pancreatic cancer using the ABC factors: a TAPS Consortium Study  Emmelie Dekker
AB25 Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac  Hidde Eijkelenkamp
AB26 The value of biological and conditional factors for staging of patients with pancreatic cancer beyond anatomical criteria: a nationwide analysis  Thijs Schouten
AB27 Impact of baseline serum CA 19-9 on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials   Deesje Doppenberg
AB28 Minimum and optimal CA19-9 Response after induction therapy in patients with locally advanced pancreatic cancer: A nationwide multicentre study  Leonard Seelen
AB29 Is standardized follow-up the optimal strategy after resection of biliary cancer?
Britte ten Haaft
AB30 Central pancreatectomy: an international retrospective multicentre study of 838 cases  Eduard van Bodegraven
Back To Top